Abstract 15216: Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction and Active Malignancy: A Propensity Matched Retrospective Analysis
Abstract
Background: Patients living with both heart failure with reduced ejection fraction (HFrEF) and active malignancy represent one of the most challenging populations in modern cardiology. Despite carrying the highest combined cardiovascular and oncologic risk, they have been excluded from every landmark sodium glucose cotransporter-2 inhibitor (SGLT-2i) trial, including DAPA-HF and EMPEROR-Reduced. Whether these guideline-recommended agents preserve their mortality and renoprotective benefits in patients simultaneously battling cancer remains urgently unanswered. Methods: A retrospective cohort study was conducted using the TriNetX Research Network spanning 113 healthcare organizations. Adults with HFrEF and concurrent active malignancy confirmed by antineoplastic therapy within six months were identified. Cohort 1 received empagliflozin or dapagliflozin within one year of heart failure diagnosis; Cohort 2 received neither. One-to-one propensity score matching on age, sex, race, hypertension, diabetes, hyperlipidemia, obesity, and prior myocardial infarction yielded 3,622 patients per group. Outcomes were assessed over three years and included all-cause mortality, acute kidney injury, progression to advanced chronic kidney disease, diabetic ketoacidosis, urinary tract infection, and all-cause hospitalization. Results: SGLT-2i use was associated with significantly lower all-cause mortality (31.0% vs. 39.7%; risk ratio 0.781; 95% CI, 0.733-0.832; hazard ratio 0.645; 95% CI, 0.597-0.698; p<0.001) and reduced progression to advanced chronic kidney disease (8.8% vs. 11.9%; risk ratio 0.736; 95% CI, 0.642-0.844; hazard ratio 0.644; p<0.001). Acute kidney injury rates were similar on time-to-event analysis (hazard ratio 0.957; p=0.236). Urinary tract infection rates were equivalent (24.1% vs. 23.4%; p=0.490). Diabetic ketoacidosis was more frequently coded in the SGLT-2i group (21.4% vs. 15.3%; p<0.001), though this likely reflects chemotherapy-related hyperglycemia captured within the outcome definition rather than true ketoacidosis. Time-to-first hospitalization was significantly delayed with SGLT-2i use (hazard ratio 0.792; p<0.001), though overall hospitalization rates were similar. Conclusion: In this large propensity-matched real-world cohort, SGLT-2i use in HFrEF patients with active malignancy was associated with meaningful survival benefit and renal protection without significant increases in acute kidney injury or urinary tract infection. These findings challenge prevailing hesitancy to prescribe these agents in oncology patients and support their broader use in cardio-oncology practice pending confirmatory prospective trials.